impedimed[®]

13 October 2021

ASX ANNOUNCEMENT

Supplementary Information: Advocate HF Program and Icon Group

Brisbane, Australia – ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, provides supplemental information regarding the following announcements:

SOZO[®] Heart Failure Program Initiated at AdvocateAuroraHealth – 27 September 2021

As announced, ImpediMed's first heart failure program was initiated at Advocate Health's Heart Institute. The announcement was made as it is of great significance for the company as it embarks on the commercialisation of the SOZO Heart Failure Application.

The initial agreement is for one SOZO device and the associated licence fees for SOZO software and services, as Advocate pilots the clinical and commercial applicability of SOZO through reimbursement. The arrangement is for an initial period of three years. The customer may terminate the program at any time after the initial twelve months of the arrangement by giving thirty days' notice. The contract value is not considered material with reference to the Company's \$10m revenue run rate, but represents a significant milestone in the initial commercialisation of Heart Failure through a pilot program in a key heart failure centre. In addition to the SOZO Heart Failure program, the Advocate Aurora Health system currently has 10 SOZO devices under a Lymphoedema Prevention Program.

New Corporate Oncology Account with Icon Group - 30 September 2021

ImpediMed announced an agreement with Icon Group for the roll out of 13 SOZO units with installation to occur over coming weeks. Icon Group is Australia's largest dedicated cancer care provider with 31 centres across Australasia.

ImpediMed's newly formed Corporate Accounts Team established the relationship and facilitated the transaction but the final contract is between Icon Group and Regional Health Care Group, ImpediMed's Australian distributor. As previously disclosed the revenue recognised through the distributor model is significantly less than through the direct sales model and the contract value is not considered material with reference to the company's \$10m revenue run rate.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact: Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit <u>www.impedimed.com</u>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.